stockrowNeogen Corporation
NEOG Healthcare Medical Devices
Neogen Corporation’s revenue for fiscal 2026 (year ended May 2026) was $870.4 million, down 2.72% from fiscal 2025.
- Revenue
- +6.50%
- EPS
- −129.4%
- Free cash flow
- +135.6%
- Total debt
- −2.31%
Quarter to August 2026, against a year earlier
Follow NEOG
Alert me
Neogen Corporation (NEOG) Net income
Neogen Corporation's net income for fiscal 2026 was −$7.9M, compared with −$1.1B in fiscal 2025. Over the twelve months to 31 August 2026 it was −$56.1M. Over the past ten years it has ranged from −$1.1B (fiscal 2025) to $63.2M (fiscal 2018); the current reading is higher than 33% of that period. Neogen Corporation ranks 124th of 149 Medical Devices companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2026 | −$7.9M | — |
| FY2025 | −$1.1B | — |
| FY2024 | −$9.4M | — |
| FY2023 | −$22.9M | — |
| FY2022 | $48.3M | (20.65%) |
| FY2021 | $60.9M | 2.37% |
| FY2020 | $59.5M | (1.16%) |
| FY2019 | $60.2M | (4.81%) |
| FY2018 | $63.2M | 43.76% |
| FY2017 | $44.0M | 20.35% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Aug 2026 | −$11.9M | — |
| May 2026 | −$11.3M | — |
| Feb 2026 | −$17.0M | — |
| Nov 2025 | −$15.9M | — |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| TMDX TransMedics Group, Inc. compare | $144.5M |
| ITGR Integer Holdings Corporation compare | $103.7M |
| INSP Inspire Medical Systems, Inc. compare | $100.7M |
| UFPT UFP Technologies, Inc. compare | $72.3M |
| AXGN AxoGen, Inc. compare | −$31.9M |
| ESTA Establishment Labs Holdings Inc. compare | −$38.9M |
| BFLY Butterfly Network, Inc. compare | −$53.7M |
| NEOG Neogen Corporation | −$56.1M |
| ALMR Alamar Biosciences, Inc. compare | −$77.7M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on NEOG
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement